Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama VA, Helmerhorst FM, Stijnen T, et al
SELECT (cardiovascular outcomes in obesity, no diabetes) The single most important data point published on semaglutide outside diabetes was the SELECT trial, Lincoff et al., NEJM 2023, PMID 37962078
GLP-1 also acts as a satiety signal by activating receptors on vagal afferent neurons that transmit signals from the gut to the hypothalamic satiety centers, including regions that regulate appetite, energy expenditure, and food reward

Other Warnings for SEMALIX 3 TABLET Before taking SEMALIX 3 TABLET, inform your doctor if you: Have or have had pancreatic problems Have a history of diabetes-related vision problems (diabetic retinopathy) Are planning to undergo or have recently undergone surgery Experience severe and persistent abdominal pain Have low blood sugar (hypoglycaemia) Notice sudden changes in vision Have delayed gastric emptying (gastroparesis) Have gastrointestinal issues, such as severe vomiting, diarrhoea, or dehydration Have gallbladder problems Who should not take SEMALIX 3 TABLET SEMALIX 3 TABLET is not recommended for use if you: Have a personal or family history of medullary thyroid carcinoma (MTC) Have an endocrine disorder known as Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Have type 1 diabetes Have developed diabetic ketoacidosis Drug - Drug interaction Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements
